RESUMO
Introduction: Vitiligo an acquired pigmentary disorderof the skin and mucous membranes characterized by wellcircumscribed, depigmented macules and patches resultingfrom selective destruction of melanocytes. CRP is an acutephase protein secreted by the liver in response to severalinflammatory cytokines such as IL6. Since inflammatoryand immune factors plays a key role in the pathogenesis ofvitiligo, we aimed to assess the relationship between theserum level of hs-CRP and pathogenesis and severity ofvitiligo.Material and methods: The study was conducted in theDept. of Biochemistry and Dept. of Dermatology andVenereology in MGM Medical College & M Y HospitalIndore after approval from ethical committee on 70Confirmed & diagnosed cases of Vitiligo patients of agegroup 18 to 55 years attending Dermatology OPD in MYHospital Indore during a period of April 2018 to April 2019.Patients were divided into three groups according to thearea of skin affected. Healthy individual without vitiligowere taken as controls. Venous blood sample was analyzedfor serum hs-CRP levels and liver function. Appropriatestatistical tests were applied on Minitab Version 17.0 and pvalues < 0.01was considered significant.Results: In our study the mean serum hs-CRP in case groupwas higher 12.09 ± 11.64 than in control group it was 1.99 ±2.05 with negative but statistically significant correlation withage of onset of disease and positive statistically significantcorrelation with duration of disease thus, serum hs-CRPlevel might be useful for evaluating the disease activity ofvitiligo as Novel biomarker.Conclusion: As high-sensitive C-reactive protein (hs-CRP)is an important sensitive diagnostic and prognostic markerin many systemic inflammatory diseases and very lowconcentrations of hs-CRP can be analyzed in the serum, itsdetection and serial measurements helps to provide a novellink to evaluate the disease activity and severity and responseto treatment
RESUMO
BACKGROUND: Propofol has recently been reported to be a safe sedative for endoscopy. METHODS: One hundred consecutive patients more than 18 years of age undergoing an endoscopic procedure were included in the study. The risk of sedation was calculated using the American Society of Anesthesiology risk class. Pregnant women, patients opting to undergo endoscopy without sedation, and those allergic to any sedative, eggs or soyabeans were excluded. A trained nurse administered propofol under the supervision of an anesthesiologist. Vital parameters, including oxygen saturation, were measured before and during the procedure. Time taken for full sedation, quantity of propofol used, duration of the procedure, time taken for recovery from sedation, and any complication during or after anesthesia were recorded. The patients scored quality of sedation, perception of pain and any memory of the procedure. RESULTS: Eighty-four patients were in ASA risk class I and II and the remaining 16 were in a higher ASA risk class. There was no difference in vital sign measurements during the endoscopic procedures as compared to baseline values. None of the patients had any complication. More than 90% of patients did not report any pain and had complete amnesia for the procedure. CONCLUSION: Propofol is a safe and effective sedative for endoscopic procedures.